Giles, H. V. http://orcid.org/0000-0001-6292-3802
Drayson, M. T. http://orcid.org/0000-0002-1528-7564
Kishore, B.
Pawlyn, C. http://orcid.org/0000-0002-7190-0028
Kaiser, M. http://orcid.org/0000-0002-3677-4804
Cook, G. http://orcid.org/0000-0003-1717-0412
de Tute, R.
Owen, R. G.
Cairns, D. http://orcid.org/0000-0002-2338-0179
Menzies, T.
Davies, F. E.
Morgan, G. J.
Pratt, G. http://orcid.org/0000-0002-6937-2852
Jackson, G. H.
Funding for this research was provided by:
British Society for Haematology (36374/ESR2020)
The Binding Site Ltd provided funding for the reagents for the mass spectrometry testing.
Article History
Received: 15 October 2023
Revised: 17 January 2024
Accepted: 22 January 2024
First Online: 18 March 2024
Competing interests
: HVG has received research funding from The Binding Site Ltd, part of Thermo Fisher Scientific. GP is on the medical advisory board and has received educational funding from Janssen Oncology; BMS-Celgene; Amgen; Takeda; The Binding Site Ltd part of Thermo Fisher Scientific; Sanofi/Aventis; Beigene; and GlaxoSmithKline.